TUESDAY, May 4, 2021 (HealthDay News) – A first study of this type suggests that slow-growing breast cancers can be treated with a very specific tumor freezing technique, eliminating the need for invasive surgery.
Tests so far suggest that the technique is effective in women over 60 with a relatively low-risk diagnosis. Lung cancer.
“Cryoablation is a minimally invasive solution that destroys breast tumors safely, quickly, and painlessly, without the need for surgery,” said study author Dr. Richard Fine, breast surgeon at West Cancer Center & Research Institute in Germantown, Tenn.
“The procedure exposes the diseased tissue to extreme cold [cryo] to destroy [ablate] “It was added.” It is performed in the office while the patient is awake. “
The new study, which involved about 200 women, found that when cryoablation was performed on women with low / low-risk breast cancer, almost all patients remained cancer-free for three years.
The mean age of the study patients was 75 years and all were diagnosed. “invasive ductal carcinoma“breast cancer. The tumors were relatively small, measuring no more than 1.5 centimeters. All patients had”hormone receptor-positive tumors “, ie tumors that were ER +, PR + and / or HER2-.
“In general, tumors that are ER + and / or PR + grow a little slower and have a slightly better prognosis than hormone receptor-negative tumors,” Fine said.
All patients in the study underwent cryoablation, which involved the direct insertion of a probe through the skin and at the site of the tumor, under localized anesthesia. In turn, liquid nitrogen was applied to freeze the target tumors from the inside out. The treatment lasted between 20 and 40 minutes, turning the tumors into ice balls.
The procedure eliminated the need for follow-up surgery, the researchers reported, although nearly 15% of women also underwent surgery. radiation, while approximately 3/4 were treated with endocrine therapy. He underwent a patient chemotherapy.
Patients were reviewed twice a year, up to five years after treatment. The result: at an average follow-up point of almost three years after treatment, only 2% (four patients) had seen their cancer return. No serious side effects were reported and almost all patients and doctors who attended stated that they were satisfied with the treatment (95% and 98%, respectively).